- Pertuzumab is a humanized monoclonal antibody that targets the HER2 receptor, used primarily in combination therapy to treat HER2-positive breast cancer by inhibiting tumor cell growth and survival
- The global pertuzumab market is experiencing steady growth, driven by the increasing prevalence of HER2-positive breast cancer, rising adoption of targeted biologics, and expansion of oncology treatment access in emerging economies
- North America is expected to dominate the global pertuzumab market with a market share of approximately 44.8% in 2025, driven by the high incidence of HER2‑positive breast cancer, advanced oncology infrastructure, and the strong presence of key industry players such as Roche
- Asia-Pacific is expected to be the fastest growing region in the global pertuzumab market, with an estimated market share of 20% through 2025, driven by rapid expansion of oncology infrastructure, rising breast cancer incidence, and growing adoption of targeted biologics
- HER2‑positive breast cancer segment is expected to dominate the market with a market share of 50.6% owing to its extensive use in both adjuvant and neoadjuvant settings. The market is driven by strong guideline endorsements for reducing recurrence risk and improving disease‑free survival
